Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 27,749 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 3 Interventional Results available

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

NCT02040779
View directory record Official record
Conditions
Persistent Asthma
Interventions
Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Withdrawn Phase 2 Interventional

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

NCT02667496
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
Sargramostim GZ402664, Placebo, Florbetapir F18
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

NCT01696396
View directory record Official record
Conditions
Crohn's Disease
Interventions
Abrilumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00932646
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Placebo, Foradil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

NCT04992546
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PRN473 (SAR444727), Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

NCT02301988
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Tucson, Arizona • Santa Barbara, California • Lakewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

NCT00409188
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
1,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
49
States / cities
Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

NCT02354703
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional Results available

A Study of TAK-994 in Adults With Narcolepsy

NCT04820842
View directory record Official record
Conditions
Narcolepsy Type 1 (NT 1)
Interventions
TAK-994, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
35
States / cities
Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dietary Treatment of Crohn's Disease

NCT00343642
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Active fructo-oligosaccharide, Placebo fructo-oligosaccharide, Diet
Drug · Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Macon, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

NCT04062669
View directory record Official record
Conditions
Virus Diseases
Interventions
Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Saline Placebo, RabAvert
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
South Miami, Florida • Lenexa, Kansas • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 13, 2026, 11:37 PM EDT
Active, not recruiting Phase 4 Interventional

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

NCT06801015
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

NCT03353350
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
efpeglenatide (SAR439977), placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Glendale, Arizona • Canoga Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

NCT03152591
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Springfield, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

NCT05602818
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs

NCT00311090
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Idrabiotaparinux sodium, Idraparinux sodium, Avidin, Placebo (for Avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 13, 2026, 11:37 PM EDT
Recruiting Phase 2Phase 3 Interventional

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo
Drug
Lead sponsor
Bicara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Not applicable Interventional

Feasibility of Using a Mobile Device Controlled Micro-pressure Pulse Insufflator for Acute Migraine Relief

NCT03263897
View directory record Official record
Conditions
Migraine
Interventions
insufflation, placebo insufflation
Device
Lead sponsor
Caps Research Network
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Prescott, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

NCT00048360
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
Extended-release bupropion hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
21
States / cities
Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Image Parkinson's Disease Progression Study

NCT02789020
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo, Magnetic Resonance Imaging, functional Magnetic Resonance Imaging, Physical Function Performance Test
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 77 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estradiol Effects on Alcohol Across the Menstrual Cycle

NCT04595682
View directory record Official record
Conditions
Alcohol Use, Unspecified
Interventions
Placebo, Alcohol
Drug
Lead sponsor
Mark Fillmore
Other
Eligibility
21 Years to 35 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial

NCT04403282
View directory record Official record
Conditions
Pseudofolliculitis Barbae
Interventions
Eflornithine Topical, Placebo Eflornithine Topical
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 13, 2026, 11:37 PM EDT
Active, not recruiting Phase 2 Interventional

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

NCT05122559
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Emmanuelle Waubant, MD PhD
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 13, 2026, 11:37 PM EDT